NCT07005128 2026-04-16
DeLLphi-312
Amgen
Phase 3 Recruiting
Clinical Trials
141 trialsNCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT07502300 2026-04-14
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT05957510 2026-04-03
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT06646276 2026-04-03
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07296809 2026-04-02
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT07472517 2026-03-31
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
NCT05815160 2026-03-30
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Active not recruiting
NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT06449209 2026-03-12
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06830694 2026-02-23
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT05353257 2026-01-13
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 3 Active not recruiting
NCT04745689 2025-12-10
TAZMAN
AstraZeneca
Phase 2 Active not recruiting
NCT04063163 2025-12-09
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Completed
NCT07245446 2025-11-24
A Study of Ivonescimab in First-Line ES-SCLC
Akeso
Phase 2 Recruiting
NCT03043872 2025-10-21
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT05599984 2025-10-20
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT04702880 2025-10-08
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07061535 2025-07-11
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT05224141 2025-07-08
KEYVIBE-008
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT06717243 2025-03-19
STRATUS
Oncology Center of Biochemical Education And Research
Recruiting
NCT04101357 2025-03-18
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
Phase 1/2 Terminated
NCT06663098 2025-03-13
CARRY-ON
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Recruiting
NCT06869239 2025-03-11
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Peking University Cancer Hospital & Institute
Recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05309629 2025-01-17
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT06780826 2025-01-17
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Recruiting